scholarly journals Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk—A Single Center Experience

2019 ◽  
Vol 8 (8) ◽  
pp. 1164 ◽  
Author(s):  
Hannes Neuwirt ◽  
Irmgard Leitner-Lechner ◽  
Julia Kerschbaum ◽  
Michael Ertl ◽  
Florian Pöggsteiner ◽  
...  
Keyword(s):  
Risk Factor ◽  
Cardiovascular Risk ◽  
Renal Transplantation ◽  
Renal Allograft ◽  
Cox Regression ◽  
De Novo ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Efficacy And Safety ◽  
High Cardiovascular Risk

Belatacept is an attractive option for immunosuppression after renal transplantation. Renal allograft function is superior when compared to calcineurin inhibitor (CNI) based therapy in “de novo” treated patients and it has also been proposed that individuals at high cardiovascular (CV) risk may benefit most. In this retrospective cohort study, we assessed the efficacy and safety of treating patients at high cardiovascular risk with Belatacept (n = 34, for 1194 observation months) when compared to a matched control group of 150 individuals under CNI immunosuppression (for 7309 months of observation). The estimated glomerular filtration rate (eGFR) increased for patients taking Belatacept but decreased during CNI-based therapy (+2.60 vs. −0.89 mL/min/1.73 m2/year, p = 0.006). In a multivariate Cox regression model, Belatacept remained the only significant factor associated with the improvement of eGFR (HR 4.35, 95%CI 2.39–7.93). Belatacept treatment was not a significant risk factor for renal allograft rejection or graft loss. In terms of safety, the only significant risk factor for de novo cardiovascular events was a pre-existing cerebrovascular disease, but Belatacept was not associated with a significant risk reduction. Belatacept treatment was not associated with an increased risk of severe infections, cytomegalo virus (CMV) or BK-virus reactivation, malignancy or death in the multivariate Cox regression analysis. Belatacept is an efficient and safe option for patients after renal transplantation at high cardiovascular risk.

Persistent Hypercalcemia Is a Significant Risk Factor for Graft Dysfunction in Renal Transplantation Recipients

2006 ◽  
Vol 38 (2) ◽  
pp. 480-482 ◽  
Author(s):  
F.N. Özdemir ◽  
B. Afsar ◽  
A. Akgul ◽  
C. Usluoğulları ◽  
A. Akçay ◽  
...  
Keyword(s):  
Risk Factor ◽  
Renal Transplantation ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Graft Dysfunction

scholarly journals Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients

2000 ◽  
Vol 13 (5) ◽  
pp. 344-350 ◽  
Author(s):  
Robert L. Madden ◽  
Jeffrey G. Mulhern ◽  
Bernard J. Benedetto ◽  
Michael H. O'Shea ◽  
Michael J. Germain ◽  
...  
Keyword(s):  
Risk Factor ◽  
Acute Rejection ◽  
Chronic Rejection ◽  
Renal Allograft ◽  
Significant Risk ◽  
Significant Risk Factor

Is African-America race (AAR) a risk factor for failure in prostate cancer (PCa)?

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 1515-1515
Author(s):  
M. J. Mann ◽  
M. C. Benson ◽  
J. M. McKiernan
Keyword(s):  
Risk Factor ◽  
Cox Regression ◽  
Significant Risk ◽  
Disease Free Survival ◽  
Significant Risk Factor ◽  
Adjunctive Treatment ◽  
Rank Test ◽  
Urologic Oncology ◽  
Interaction Terms ◽  
Time Periods

1515 Background: There is much disagreement as to whether AAR is an independent negative risk factor in biochemical disease-free survival (BCDFS) of PCa. Much of the literature suggests that AAR is a negative risk factor of BCDFS. However, the past decade has seen improvements in treatments that may have affected outcomes in PCa. Thus, we sought to determine if AAR is an independent risk factor for BCDFS in a modern cohort of PCa patients. Methods: A retrospective review of The Columbia Urologic Oncology Database was performed. From ‘91-‘06, 2,747 patients underwent radical prostatectomy and did not receive adjunctive treatment. Of these, 252 (9%) patients were AAR, and 2495 were not of African-American Race (NAAR). Of the NAAR patients, 1,907 (69%) were Caucasian, and 588 (21%) were of other or unknown race. BCDFS was defined as time to first rise in PSA (>0.1ng/mL) or use of secondary therapy after surgery. Patients were stratified based on race (AAR vs NAAR) and year of surgery. BCDFS was evaluated using Kaplan-Meier (KM) analysis with log- rank test. Multivariate Cox regression models were fit and interaction terms were tested with Wall’s test to determine the significance of AAR on BCDFS over 3 time periods (91–95, 96–00, and 01–06). Results: The patients had a median age 61.9 yrs, pathological Gleason sum (GS) 7, and mean PSA 7.7. In KM analysis, AAR was a negative risk factor of BCDFS (p<0.01) over all time periods, had lower mean age at surgery (p<0.01), higher pre-operative PSA (p<0.01), and higher GS (p<0.01). Not surprisingly, once PSA, GS, and stage were controlled across time cohorts, AAR lost significance as a risk factor (p=0.46). When Wall’s test was used to compare the results of a multivariate analysis controlling for the same variables and stratified by time, it was found that outcomes improved over time in patients of AAR and NAAR (p<0.01), but there was no difference between the two groups (p=0.99). Conclusions: Despite previous reports that AAR is an independent negative predictor of outcome, it only appeared to be a negative risk factor in univariate analyses. Despite higher PSA, and GS, AAR was no longer a significant risk factor. Additionally, when stratified by time, patients in more contemporary cohorts had improved outcomes, with no differences between AAR and NAAR patients. No significant financial relationships to disclose.

scholarly journals Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy: Systematic Review and Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Szilárd Váncsa ◽  
Dávid Németh ◽  
Péter Hegyi ◽  
Zsolt Szakács ◽  
Ádám Farkas ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Risk Factor ◽  
De Novo ◽  
Meta Analysis ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Predictive Risk Factor ◽  
Direct Acting

Background: Hepatitis C virus (HCV)-infected patients treated with direct-acting antivirals (DAAs) are still at risk of developing hepatocellular carcinoma (HCC) after sustained virologic response (SVR). This study aimed to investigate the role of diabetes mellitus (DM) as a potential predictive risk factor in developing de novo HCC in HCV-infected patients after DAA treatment.Methods: This study was registered on PROSPERO under registration number CRD42021230457. We performed a systematic search in four medical databases from inception through November 3rd, 2020. Studies were eligible if they reported on HCV-infected patients treated with DAAs and compared the frequency of de novo HCC in patients with and without DM. We calculated pooled odds ratios, unadjusted (UHR), and adjusted hazard ratios (AHR) with 95% confidence intervals (CIs) in meta-analysis.Results: We included 30 articles in our systematic review and meta-analysis. DM proved to be a significant risk factor of HCC in DAA-treated HCV patients in unadjusted (UHR = 1.44, CI: 1.15–1.79) and adjusted analyses (AHR = 1.31, CI: 1.06–1.62). In the group of patients achieving SVR after DAA therapy, DM increased the risk of HCC in unadjusted (UHR = 1.3, CI: 1.09–1.51) analysis; however, in adjusted results, the risk was non-significant (AHR = 1.07, CI: 0.89–1.28). In patients with advanced liver fibrosis, DM was a risk factor for HCC in adjusted (AHR = 1.36, CI: 1.03–1.8), but not in unadjusted analysis (UHR = 1.11, CI: 0.8–1.42).Conclusions: DM is an independent risk factor of de novo HCC after DAA treatment in HCV-infected patients.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=230457, identifier: CRD42021230457.

Physical Illness and Suicide Risk in Rural Residents of Contemporary China

Crisis ◽  
2014 ◽  
Vol 35 (5) ◽  
pp. 330-337 ◽  
Author(s):  
Cun-Xian Jia ◽  
Lin-Lin Wang ◽  
Ai-Qiang Xu ◽  
Ai-Ying Dai ◽  
Ping Qin
Keyword(s):  
Risk Factor ◽  
Family Income ◽  
Rural China ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Health Condition ◽  
Physical Illness ◽  
Rural Residents ◽  
Increased Risk ◽  
Study Population

Background: Physical illness is linked with an increased risk of suicide; however, evidence from China is limited. Aims: To assess the influence of physical illness on risk of suicide among rural residents of China, and to examine the differences in the characteristics of people completing suicide with physical illness from those without physical illness. Method: In all, 200 suicide cases and 200 control subjects, 1:1 pair-matched on sex and age, were included from 25 townships of three randomly selected counties in Shandong Province, China. One informant for each suicide or control subject was interviewed to collect data on the physical health condition and psychological and sociodemographic status. Results: The prevalence of physical illness in suicide cases (63.0%) was significantly higher than that in paired controls (41.0%; χ2 = 19.39, p < .001). Compared with suicide cases without physical illness, people who were physically ill and completed suicide were generally older, less educated, had lower family income, and reported a mental disorder less often. Physical illness denoted a significant risk factor for suicide with an associated odds ratio of 3.23 (95% CI: 1.85–5.62) after adjusted for important covariates. The elevated risk of suicide increased progressively with the number of comorbid illnesses. Cancer, stroke, and a group of illnesses comprising dementia, hemiplegia, and encephalatrophy had a particularly strong effect among the commonly reported diagnoses in this study population. Conclusion: Physical illness is an important risk factor for suicide in rural residents of China. Efforts for suicide prevention are needed and should be integrated with national strategies of health care in rural China.

scholarly journals Higher premature atrial complex burden from the Holter examination predicts poor cardiovascular outcome

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ting-Chun Huang ◽  
Po-Tseng Lee ◽  
Mu-Shiang Huang ◽  
Pei-Fang Su ◽  
Ping-Yen Liu
Keyword(s):  
Risk Factor ◽  
Dose Response ◽  
Cox Model ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Cardiovascular Death ◽  
Specific Model ◽  
Distribution Model ◽  
All Cause Mortality ◽  
Quartile Group

AbstractPremature atrial complexes (PACs) have been suggested to increase the risk of adverse events. The distribution of PAC burden and its dose–response effects on all-cause mortality and cardiovascular death had not been elucidated clearly. We analyzed 15,893 patients in a medical referral center from July 1st, 2011, to December 31st, 2018. Multivariate regression driven by ln PAC (beats per 24 h plus 1) or quartiles of PAC burden were examined. Older group had higher PAC burden than younger group (p for trend < 0.001), and both genders shared similar PACs distribution. In Cox model, ln PAC remained an independent risk factor for all-cause mortality (hazard ratio (HR) = 1.09 per ln PAC increase, 95% CI = 1.06‒1.12, p < 0.001). PACs were a significant risk factor in cause-specific model (HR = 1.13, 95% CI = 1.05‒1.22, p = 0.001) or sub-distribution model (HR = 1.12, 95% CI = 1.04‒1.21, p = 0.004). In ordinal PAC model, 4th quartile group had significantly higher risk of all-cause mortality than those in 1st quartile group (HR = 1.47, 95% CI = 1.13‒1.94, p = 0.005), but no difference in cardiovascular death were found in competing risk analysis. In subgroup analysis, the risk of high PAC burden was consistently higher than in low-burden group across pre-specified subgroups. In conclusion, PAC burden has a dose response effect on all-cause mortality and cardiovascular death.

Comorbidity and severity-of-illness risk adjustment for hospital-onset Clostridioides difficile infection using data from the electronic medical record

2020 ◽  
pp. 1-7
Author(s):  
Stephanie M. Cabral ◽  
Katherine E. Goodman ◽  
Natalia Blanco ◽  
Surbhi Leekha ◽  
Larry S. Magder ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Risk Adjustment ◽  
Community Hospital ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Bivariate Analysis ◽  
Patient Admissions ◽  
Clostridioides Difficile ◽  
Risk Adjustment Model

Abstract Objective: To determine whether electronically available comorbidities and laboratory values on admission are risk factors for hospital-onset Clostridioides difficile infection (HO-CDI) across multiple institutions and whether they could be used to improve risk adjustment. Patients: All patients at least 18 years of age admitted to 3 hospitals in Maryland between January 1, 2016, and January 1, 2018. Methods: Comorbid conditions were assigned using the Elixhauser comorbidity index. Multivariable log-binomial regression was conducted for each hospital using significant covariates (P < .10) in a bivariate analysis. Standardized infection ratios (SIRs) were computed using current Centers for Disease Control and Prevention (CDC) risk adjustment methodology and with the addition of Elixhauser score and individual comorbidities. Results: At hospital 1, 314 of 48,057 patient admissions (0.65%) had a HO-CDI; 41 of 8,791 patient admissions (0.47%) at community hospital 2 had a HO-CDI; and 75 of 29,211 patient admissions (0.26%) at community hospital 3 had a HO-CDI. In multivariable regression, Elixhauser score was a significant risk factor for HO-CDI at all hospitals when controlling for age, antibiotic use, and antacid use. Abnormal leukocyte level at hospital admission was a significant risk factor at hospital 1 and hospital 2. When Elixhauser score was included in the risk adjustment model, it was statistically significant (P < .01). Compared with the current CDC SIR methodology, the SIR of hospital 1 decreased by 2%, whereas the SIRs of hospitals 2 and 3 increased by 2% and 6%, respectively, but the rankings did not change. Conclusions: Electronically available patient comorbidities are important risk factors for HO-CDI and may improve risk-adjustment methodology.

Sign in / Sign up

Export Citation Format

Share Document